How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Neurology

Volumn 69, Issue 15, 2007, Pages 1498-1507

  Brown, M G ^a,b,d   Kirby, S ^b   Skedgel, C ^b   Fisk, J D ^b   Murray, T J ^b   Bhan, V ^b   Sketris, I S ^b,c  

^a Capital Health District   (Canada)

^b Dalhousie University ^*  (Canada)

^c DALHOUSIE UNIVERSITY   (Canada)

^d Centre for Clinical Research   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA1 INTERFERON; BETA1A INTERFERON; CENTRAL NERVOUS SYSTEM AGENTS; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG PULSE THERAPY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; POPULATION RESEARCH; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 35148881670     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000271884.11129.f3     Document Type: Article

References (37)

1. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-661.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294.
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-1276.
4. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-1285.
5. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-1504.
6. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on Interferon Beta-1b in Secondary Progressive MS. Lancet 1998;352:1491-1497.
7. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
8. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-1504.
9. National Institute for Clinical Medicine. Multiple sclerosis: management of multiple sclerosis in primary and secondary care. NICE Technical Appraisal Guidance no. 8. 2003.
10. Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
11. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-708.
12. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-266.
13. Long-term efficacy of interferon-beta-1a in relapsing MS. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4. Neurology 2001;56:1628-1636.
14. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49:290-297.
15. Kappos L, Polman C, Pozzilli C, et al. Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS. Neurology 2001;57:1969-1975.
16. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology 2004;63:1779-1787.
17. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet 2003;361:545-552.
18. Cohen JA, Antel JP. Does interferon beta help in secondary progressive MS? Neurology 2004;63:1768-1769.
19. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
20. Johnson KP, Panitch HS, Ford CC, et al. Long-term slowing of disability progression in patients receiving continuous glatiramer acetate compared with those withdrawing from therapy: 10 year results from an ongoing trial. Neurology 2004;62:A180.
21. The North American Study Group on Interferon Beta-1b in Secondary Progressive MS. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study. Neurology 2004;63:1788-1795.
22. Namaka M, Pollitt-Smith M, Gupta A, et al. The clinical importance of neutralizing antibodies in relapsing-remitting multiple sclerosis. Curr Med Res Opin 2006;22:223-239.
23. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
24. Kinkel RP, Kollman C, O'Connor P, et al. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006;66:678-684.
25. Ebers GC, Rice G, Wolf C, et al. 16 year long-term follow-up of interferon beta 1b treatment in patients with multiple sclerosis. Mult Scler 2005;11 (suppl 1):S156.
26. Rudick RA, Cutter GR, Baier M, et al. Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult Scler 2005;11:626-634.
27. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-953.
28. Weinshenker BG, Sibley WA. Natural history and treatment of multiple sclerosis. Curr Opin Neurol Neurosurg 1992;5:203-211.
29. Paty DW, Ebers GC. Multiple sclerosis. Philadelphia: FA Davis Co, 1998.
30. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group. Neurology 1999;53:679-686.
31. Freedman MS, Francis GS, Sanders EA, et al. Randomized study of once-weekly interferon beta-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Mult Scler 2005;11:41-45.
32. Torrance GW, Furlong W, Feeny D, Boyle M. Multiattribute preference functions: Health Utilities Index. Pharmacoeconomics 1995;7:503-520.
33. Greene WH. Econometric analysis. Upper Saddle River, NJ: Prentice Hall, 2000.
34. Stata statistical software [computer program]. Version release 8.0. College Station, TX.
35. Tremlett H, Paty D, Devonshire V. Disability progression in multiple sclerosis is slower than previously reported. Neurology 2006;66:172-177.
36. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116 (pt 1):117-134.
37. Fisk JD, Brown MG, Sketris IS, Metz LM, Murray TJ, Stadnyk KJ. A comparison of health utility measures for the evaluation of multiple sclerosis treatments. J Neurol Neurosurg Psychiatry 2005;76:58-63.